Table 1.
Summary of dominant T cell epitopes
ProteinSequenceTested HLAActual HLA restrictionELISpot response rate (%)Intracellular stainingTetramer staining
12-d stimulationEx vivo (%)a
pp65/UL83495–503 NLVPMVATVb A*02:01 A*02:01 75.0 100.0 CD8 Positive 
US874–82 GVLDAVWRV A*02:01 A*02:01 72.2 50.0 CD8 Positive 
UL150A152–161 ALWDVALLEV A*02:01 A*02:01 71.4 25.0 CD8 Positive 
gM/UL100200–208 TLIVNLVEV A*02:01 A*02:01 55.0 25.0 CD8 Positive 
UL44259–267 GLFAVENFL A*02:01 HLA-II 53.9 0.0 CD4 Not tested 
UL16162–170 YPRPPGSGLb B*07:02 B*07:02 86.4 25.0 Negative Positive 
pp65/UL83417–426 TPRVTGGGAMb B*07:02 B*07:02 81.6 100.0 CD8 Positive 
TRS1166–174 SPRDAWIVL B*07:02 B*07:02 68.2 20.0 CD8 Positive 
UL52349–357 SPSRDRFVQL B*07:02 B*07:02 66.7 33.3 Negative Positive 
UL2322–30 RPWKPGQRV B*07:02 B*07:02 53.6 66.7 CD8 Positive 
UL4676–84 SPRHLYISL B*07:02 B*07:02 50.0 0.0 CD4/CD8 Positive 
UL112/UL113125–134 SENGNLQVTY B*44:02 B*44:02 83.9 62.5 CD8 Positive 
UL117358–366 HETGVYQMW B*44:02 B*44:02 65.4 62.5 CD8 Positive 
UL105715–723 YADPFFLKYb A*01:01 A*01:01 100.0 90.9 CD8 Positive 
UL44245–253 VTEHDTLLYb A*01:01 A*01:01 92.9 100.0 CD8 Positive 
UL69569–578 RTDPATLTAY A*01:01 A*01:01 82.6 66.7 CD8 Positive 
US28122–130 ITEIALDRY A*01:01 A*01:01 58.3 14.3 CD8 Positive 
gB/UL55657–665 NTDFRVLELY A*01:01 A*01:01 56.3 0.0 CD8 Positive 
UL77228–236 GLYTQPRWK A*03:01 A*03:01 76.2 50.0 CD8 Positive 
UL57790–798 RVKNRPIYR A*03:01 A*03:01 60.9 33.3 CD8 Positive 
UL34180–188 LPHERHREL B*08:01 B*08:01 90.9 85.7 CD8 Positive 
UL2661–69 LPYPRGYTL B*08:01 B*08:01/51:01/14:02 68.8 16.7 CD8 Positive 
UL13465–473 YLVRRPMTI B*08:01 B*08:01 50.0 33.3 Negative Positive 
pp65/UL83116–123 LPLKMLNIb B*51:01 B*51:01 80.0 87.5 CD8 Positive 
UL38156–164 FPVEVRSHV B*51:01 B*51:01 65.2 0.0 CD8 Positive 
UL2661–69 LPYPRGYTL B*51:01 B*08:01/51:01/14:02 62.5 33.3 CD8 Positive 
UL56503–511 DARSRIHNV B*51:01 B*51:01 53.3 20.0 CD8 Positive 
ProteinSequenceTested HLAActual HLA restrictionELISpot response rate (%)Intracellular stainingTetramer staining
12-d stimulationEx vivo (%)a
pp65/UL83495–503 NLVPMVATVb A*02:01 A*02:01 75.0 100.0 CD8 Positive 
US874–82 GVLDAVWRV A*02:01 A*02:01 72.2 50.0 CD8 Positive 
UL150A152–161 ALWDVALLEV A*02:01 A*02:01 71.4 25.0 CD8 Positive 
gM/UL100200–208 TLIVNLVEV A*02:01 A*02:01 55.0 25.0 CD8 Positive 
UL44259–267 GLFAVENFL A*02:01 HLA-II 53.9 0.0 CD4 Not tested 
UL16162–170 YPRPPGSGLb B*07:02 B*07:02 86.4 25.0 Negative Positive 
pp65/UL83417–426 TPRVTGGGAMb B*07:02 B*07:02 81.6 100.0 CD8 Positive 
TRS1166–174 SPRDAWIVL B*07:02 B*07:02 68.2 20.0 CD8 Positive 
UL52349–357 SPSRDRFVQL B*07:02 B*07:02 66.7 33.3 Negative Positive 
UL2322–30 RPWKPGQRV B*07:02 B*07:02 53.6 66.7 CD8 Positive 
UL4676–84 SPRHLYISL B*07:02 B*07:02 50.0 0.0 CD4/CD8 Positive 
UL112/UL113125–134 SENGNLQVTY B*44:02 B*44:02 83.9 62.5 CD8 Positive 
UL117358–366 HETGVYQMW B*44:02 B*44:02 65.4 62.5 CD8 Positive 
UL105715–723 YADPFFLKYb A*01:01 A*01:01 100.0 90.9 CD8 Positive 
UL44245–253 VTEHDTLLYb A*01:01 A*01:01 92.9 100.0 CD8 Positive 
UL69569–578 RTDPATLTAY A*01:01 A*01:01 82.6 66.7 CD8 Positive 
US28122–130 ITEIALDRY A*01:01 A*01:01 58.3 14.3 CD8 Positive 
gB/UL55657–665 NTDFRVLELY A*01:01 A*01:01 56.3 0.0 CD8 Positive 
UL77228–236 GLYTQPRWK A*03:01 A*03:01 76.2 50.0 CD8 Positive 
UL57790–798 RVKNRPIYR A*03:01 A*03:01 60.9 33.3 CD8 Positive 
UL34180–188 LPHERHREL B*08:01 B*08:01 90.9 85.7 CD8 Positive 
UL2661–69 LPYPRGYTL B*08:01 B*08:01/51:01/14:02 68.8 16.7 CD8 Positive 
UL13465–473 YLVRRPMTI B*08:01 B*08:01 50.0 33.3 Negative Positive 
pp65/UL83116–123 LPLKMLNIb B*51:01 B*51:01 80.0 87.5 CD8 Positive 
UL38156–164 FPVEVRSHV B*51:01 B*51:01 65.2 0.0 CD8 Positive 
UL2661–69 LPYPRGYTL B*51:01 B*08:01/51:01/14:02 62.5 33.3 CD8 Positive 
UL56503–511 DARSRIHNV B*51:01 B*51:01 53.3 20.0 CD8 Positive 
a

Ex vivo ELISpot assays were performed using donor samples that were positively tested in ELISpot assays with prior 12-d stimulation.

b

Previously published epitope; references in Table S1.

or Create an Account

Close Modal
Close Modal